Amgen's Acquisition Of Onyx Pharmaceuticals Transcript @ http://www.earningsimpact.com/Transcript/83254/AMGN/Amgenandapos;s-Acquisition-Of-Onyx-Pharmaceuticals#sthash.MfKJREjq.dpufFirst, I'd like to emphasize that we felt this opportunity was strategically compelling for us, enabling us to build on our strength and oncology in area in which we are one of the world's leaders with revenues of about $7 billion in 2012 and to add to our long-term growth prospects, while adding real value for our shareholders. Multiple myeloma is an area of interest to us given the emerging opportunities to address important unmet medical needs there and the rapidly growing demand for innovative therapies in this disease.
We were able to spend considerable time with Tony Coles and his team with Onyx closely reviewing the prospects for Kyprolis and obviously came away impressed with this profile as a potent and well tolerated proteasome inhibitor that we think will become a very important factor in treating multiple myeloma.